We aim to make drugs more effective through targeted delivery and improved stability, and use drying technologies and thermal analysis to help in this goal. We have improved freeze-drying methods for commercial formulations including antibiotics, hormones and vaccines. We have also developed a range of formulations that stabilise sensitive drugs and improve their uptake across biological barriers including mucosal tissue and biofilm. The Vaccinetab technology was developed for vaccines, while Stabilitab is suitable for a wider range of molecules and delivery routes. Both technologies stabilize drugs without refrigeration and are amenable to a range of presentations and delivery routes including nasal, pulmonary, vaginal and injectables.
Other Interests: Crystal engineering including polymorphism and amorphous forms. Lyophilisation for stabilisation of tissue and diagnostics.